SMITHKLINE BEECHAM's PLANS FOR TUMS WHEN TAGAMET GOES OTC
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM's PLANS FOR TUMS WHEN TAGAMET GOES OTC include continued marketing emphasis on the calcium benefits offered by the antacid, SmithKline Beecham Consumer Healthcare Chairman Harry Grogme told security analysts at a Dec. 12 meeting in New York City. "Our plans remain to invest heavily behind Tums, to position it appropriately in the antacid category so that we continue to invest behind our calcium story," he said.